Receive updates from Drug Discovery and Development for free, starting right now.
We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.
This way you won't miss any new article from Drug Discovery and Development. Unsubscribe at any time.
Site title: Drug Discovery & Development | Pharma and Biotech Insights
Is this your feed? Claim it!
By one measure, Alphabet-controlled Isomorphic Labs would tower over every company on this list. The AI drug discovery company has raised $2.7 billion in external financing, including a $2.1 billion Series B announced in May. Its corporate structure, however, puts it outside our definition of an independent biotech startup: Alphabet still controls at least 75%…
The pos...
Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the op...
Novo Nordisk’s ziltivekimab, an investigational human monoclonal antibody that targets the IL-6 ligand, a pro-inflammatory cytokine, to reduce cardiovascular inflammation, did not reduce the risk of major adverse cardiovascular events (MACE) in a Phase 3 trial. “Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this popul...
The U.S. entered August with more measles cases so far this year than it recorded during all of 2025. With kindergarten MMR coverage down to 92.5% from 95.2% before the pandemic, and Stanford modeling published in JAMA projecting measles could become endemic again within roughly two decades at current rates, President Donald Trump issued a…
The post
The clinical-stage biotech Cocrystal Pharma is developing a single treatment that targets the essential parts of the proteins a virus needs to replicate, meaning it could one day be used across multiple viruses. Its lead candidate, CDI-988, is in development for both norovirus and coronavirus. Cocrystal’s CDI-988 is a pan-viral protease inhibitor. The company completed a Pha...